HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

amubarvimab

Also Known As:

BRII-196

Networked: 10 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zhu, Qing: 4 articles (05/2024 - 01/2022)
2.	Margolis, David: 3 articles (05/2024 - 01/2022)
3.	Ma, Ji: 3 articles (01/2023 - 01/2022)
4.	Zhang, Zheng: 3 articles (12/2022 - 01/2022)
5.	ACTIV-2/A5401 Study Team: 2 articles (05/2024 - 01/2023)
6.	Chew, Kara W: 2 articles (05/2024 - 01/2023)
7.	Choudhary, Manish C: 2 articles (05/2024 - 01/2023)
8.	Currier, Judith S: 2 articles (05/2024 - 01/2023)
9.	Daar, Eric S: 2 articles (05/2024 - 01/2023)
10.	Deo, Rinki: 2 articles (05/2024 - 01/2023)

Related Diseases

1.	COVID-19 01/01/2023 - "Amubarvimab plus romlusevimab was safe and significantly reduced the risk for hospitalization and/or death among nonhospitalized adults with mild to moderate SARS-CoV-2 infection at high risk for progression to severe disease. " 08/01/2022 - "This article summarizes the milestones in the development of amubarvimab/romlusevimab leading to this first approval for the treatment of COVID-19." 01/01/2022 - "Conclusion: BRII-196 and BRII-198 are safe, well-tolerated, and suitable therapeutic or prophylactic options for SARS-CoV-2 infection. " 06/05/2023 - "Effect of the Timing of Amubarvimab/Romlusevimab (BRII-196/198) Administration on Progression to Severe Disease in Elderly Patients with COVID-19 Infection: A Retrospective Cohort Study." 01/01/2023 - "Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19."
2.	Infections 12/15/2022 - "The results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection." 06/05/2023 - "Effect of the Timing of Amubarvimab/Romlusevimab (BRII-196/198) Administration on Progression to Severe Disease in Elderly Patients with COVID-19 Infection: A Retrospective Cohort Study." 01/01/2022 - "In a Syrian golden hamster model of SARS-CoV-2 infection, animals receiving combination of amubarvimab and romlusevimab either pre- or post-infection demonstrated less weight loss, significantly decreased viral load in the lungs, and reduced lung pathology compared to controls. "
3.	Disease Progression 05/08/2024 - "Participants were non-hospitalized adults at higher risk of clinical progression randomized to amubarvimab plus romlusevimab or placebo. "
4.	Weight Loss (Weight Reduction) 01/01/2022 - "In a Syrian golden hamster model of SARS-CoV-2 infection, animals receiving combination of amubarvimab and romlusevimab either pre- or post-infection demonstrated less weight loss, significantly decreased viral load in the lungs, and reduced lung pathology compared to controls. "
5.	Communicable Diseases (Infectious Diseases) 12/15/2022 - "We evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. "

Related Drugs and Biologics

1.	romlusevimab
2.	Monoclonal Antibodies
3.	sotrovimab
4.	Neutralizing Antibodies
5.	Proteins (Proteins, Gene)
6.	Nucleic Acids
7.	Immunoglobulin G (IgG)

Related Therapies and Procedures

1.	Therapeutics